Litigation Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2023-11-07
Court	District Court, N.D. West Virginia	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	7,094,781
Link to Docket	External link to docket

The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2024-03-22	18	Answer to Complaint	United States Patent Nos. 7,094,781 (“the ’781 patent”) and 10,946,015 (“the ’015 patent”) (collectively… be a patent infringement action alleging infringement of United States Patent Nos. 7,094,781 (“the’781…: INVALIDITY OF U.S. PATENT NO. 7,094,781 The claims of the ’781 patent are invalid for failure…AFFIRMATIVE DEFENSE: NONINFRINGEMENT OF U.S. PATENT NO. 7,094,781 Mylan has not infringed, induced…’781 patent”) and 10,946,015 (“the ’015 patent”) pursuant to the patent laws of the United States, 35	External link to document
2024-04-12	20	Amended Complaint	United States Patent Nos. 7,094,781 (“the ’781 patent”) and 10,946,015 (“the ’015 patent”) (collectively…781 patent, titled “Sulfamides and Their Use as Endothelin Receptor Antagonists.” The ’781 patent duly… the ’781 patent is attached as Exhibit A. 17. Actelion Ltd owns the ’015 patent, titled “…Pyrimidine-Sulfamide.” The ’015 patent duly and legally issued on March 16, 2021. A copy of the ’015 patent is attached …contentions regarding patent validity, Mylan’s Notice Letter with respect to the ’781 patent does not identify	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document